Pharming Group faces investor probe over potential securities law violations
Pharming Group (PHAR) is under investigation by Levi & Korsinsky for alleged securities law violations. The probe follows a reported 10% year-over-year sales decline for its RUCONEST product in Q2 2026.
Law firm Levi & Korsinsky is investigating Pharming Group (PHAR) for potential violations of securities laws, on behalf of the company's shareholders. The investigation was initiated following recent financial disclosures.
The probe comes after Pharming Group reported a 10% year-over-year decline in sales for its legacy product, RUCONEST, during the second quarter of 2026. The company's stock price fell by 22% on the day this sales information was made public.
While specific details of the investigation remain undisclosed, it centers on whether the company's management engaged in conduct or made disclosures that may have violated federal securities laws. Shareholders who purchased Pharming Group stock are encouraged to contact Levi & Korsinsky for more information.
Pharming Group is a global biopharmaceutical company focused on developing and delivering treatments for rare diseases. RUCONEST is a key product used for the treatment of hereditary angioedema.